A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice

AstraZeneca1 个研究点分布在 1 个国家目标入组 5,137 人开始时间: 2007年7月最近更新: 2020年1月18日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: AstraZeneca
入组人数: 5,137
试验地点: 1

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

This patient follow-up programme was designed to describe the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy in routine clinical practice in comparison with the already documented use of Symbicort as maintenance and reliever therapy in clinical therapies

研究设计

研究类型: Observational
观察模型: Case Only
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this programme
•signed and dated informed consent(ICF)
•for patients under-age, signed and dated ICF form from both the patient and the patient's parent/legal guardian is required

排除标准

•Involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)

研究者

发起方

AstraZeneca

申办方类型

Industry

研究点 (1)

Loading locations...

相似试验

已完成

不适用

Symbicort SMART (Symbicort Maintenance And Reliever Therapy)Asthma

NCT00523679AstraZeneca2,000

已完成

3 期

Gemini Symbicort pMDIMild or Moderate Asthma

NCT00646516AstraZeneca615

已完成

4 期

Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.Chronic Obstructive Pulmonary Disease, COPD

NCT00496470AstraZeneca660

已完成

4 期

Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in MalaysiaAsthma

NCT00576316AstraZeneca201

已完成

3 期

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent AsthmaAsthma

NCT00419757AstraZeneca558